Indication: Jaundice
A phase 2B, mulit-center, single dose, blinded, randomized, placebo-controlled, dose escalation, safety and efficacy trial of Stannsoporfin in neonates with Hyperbilirubinemia.
Sub-indication: Jaundice
Study Type: Drug Study
Principal Investigator: Dan Stewart, M.D.Norton Children's Neonatology, affiliated with the UofL School of Medicine
Sponsor: Sponsor: InfaCare Pharmaceutical Corporation